Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Goltz

Vascular Surgery Flint, MI Medical Doctor

NPI 1689829673 CMS profile 212950

5020 W Bristol Rd, Flint, MI 48507

Open in the dashboard

General payments

$6,368

78 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,850 paid to institutions, not to them · program year 2020

Through program year 2025, Christopher Goltz of Flint, MI is reported in the CMS Open Payments database as having received $6,368 across 78 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,850 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 56th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $880 15
2024 General $2,529 15
2023 General $633 9
2022 General $486 5
2021 General $658 10
2020 General $574 8
2019 General $608 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Goltz
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Christopher Goltz were reported at $880. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Christopher Goltz Vascular Surgery median Middle half National median
2019 $608 $796 $226–$2,363 $163
2020 $574 $348 $118–$1,110 $114
2021 $658 $471 $158–$1,421 $132
2022 $486 $725 $222–$2,183 $149
2023 $633 $836 $257–$2,440 $160
2024 $2,529 $909 $252–$2,619 $164
2025 $880 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. W. L. Gore & Associates, Inc. $4,840 43 payments
  2. Bard Peripheral Vascular, Inc. $314 11 payments
  3. Medtronic, Inc. $193 2 payments
  4. Abbott Laboratories $157 2 payments
  5. Silk Road Medical, Inc. $134 1 payment
  6. Cardiovascular Systems Inc. $120 1 payment
  7. Smith+Nephew, Inc. $100 2 payments
  8. Stryker Corporation $96 1 payment
  9. Solventum Corporation $90 2 payments
  10. Janssen Pharmaceuticals, Inc $86 1 payment
  11. Other $239 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,620 72 payments
  2. Travel and Lodging $1,713 4 payments
  3. Education $35 2 payments
Products named General payments · program years 2019–2025
  1. GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis $2,029 9 payments
  2. GORE VIABAHN VBX Balloon Expandable Endo $763 8 payments
  3. EXCLUDER AAA Endoprosthesis $539 5 payments
  4. GORE VIABAHN Endoprosthesis with Heparin $312 3 payments
  5. EXCLUDER Conformable AAA Endoprosthesis with Active Control $244 3 payments
  6. GORE VIABAHN Endoprosthesis $223 2 payments
  7. VIABAHN VBX Balloon Expandable Endoprosthesis $191 4 payments
  8. VIABAHN Endoprosthesis with PROPATEN Bioactive Surface $176 2 payments
  9. ENDURANT IIS $164 1 payment
  10. ESPRIT $157 2 payments
  11. Other $1,901 44 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

163

Median for Vascular Surgery: 122

Drug cost

$17,725

Median for Vascular Surgery: $14,135

Branded share of claims

46%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 16 $15,237
Clopidogrel Clopidogrel Bisulfate Brand 59 $1,031
Atorvastatin Calcium Generic 52 $734
Cilostazol Generic 20 $712
Alprazolam Generic 16 $11

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 114 billing codes

Paid by Medicare

$339,660

Of which drugs: $451

Medicare patients

711

Average age 71

Services billed

5,153

326 women, 385 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 68%
Ischemic heart disease 60%
Diabetes 58%
Heart failure 52%
Arthritis 52%
Atrial fibrillation 40%
COPD 38%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 100 3,194 $327
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml Q9966 Office 25 431 $123

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kcentra
  • CSL Behring $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

78 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record